The Potent and Selective AMPK Inhibitor BAY-3827 Shows Strong Efficacy in Androgen-Dependent Prostate Cancer Models

Clara Lemos(Bayer (Germany)), Bernard Haendler(Bayer (Germany))

Research Square

July 29, 2020

10.21203/rs.3.rs-47637/v1

Cited by 1

Related Papers

The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models

|Cellular Oncology|2021|42

Dual targeting of the androgen receptor and <scp>PI3K</scp> / <scp>AKT</scp> / <scp>mTOR</scp> pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis

|Molecular Oncology|2024|20

Comparative Proteomic and Transcriptomic Analysis of the Impact of Androgen Stimulation and Darolutamide Inhibition

|Cancers|2022|3